Inventor · disambiguated record
Cheng Liao
Also filed as: LIAO CHENG · Liao cheng hao
5 granted patents·24 pending applications·0 citations·filing 2019–2025
59Inventor score
Files withJIANGSU HENGRUI MEDICINE CO9JIANGSU HENGRUI PHARMACEUTICALS CO LTD8SHANGHAI SENHUI MEDICINE CO LTD3MANYSMART THERAPEUTICS INC2SHANGHAI REGENELEAD THERAPIES CO LTD2
Top patents by PatentIndex Score
29 records- 0160US10857146B2Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitorJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 8, 2020·0 cites·12 claims
- 0259US12227583B2Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical useJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Feb 18, 2025·0 cites·17 claims
- 0359US2025026842A1Modified protein or polypeptideJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0457US2024252679A1Recombinant adeno-associated virus having variant capsid, and application thereofSHANGHAI REGENELEAD THERAPIES CO LTD·Filed 2022·Application pending·0 cites
- 0556US2025340661A1Anti cd40 antibody, antigen binding fragment and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0656US2025051750A1Aadc/gdnf polynucleotide, and use thereof in treating parkinson's diseaseSHANGHAI REGENELEAD THERAPIES CO LTD·Filed 2022·Application pending·0 cites
- 0754US12269863B2Bispecific T cell engager and uses thereofMANYSMART THERAPEUTICS INC·Filed 2019·Granted Apr 8, 2025·0 cites·14 claims
- 0854US2024075158A1Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0954US2024376204A1Protein specifically binding to pd-1 and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1053US12240904B2Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Mar 4, 2025·0 cites·16 claims
- 1153US2025051467A1Fap/cd40 binding molecule and medicinal use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1252US2025152722A1Drug conjugate of glucocorticoidSHANGHAI SHENGDI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1352US2024010754A1Multispecific antigen binding proteinJIANGSU HENGRUI MEDICINE CO·Filed 2021·Application pending·0 cites
- 1452US2024209114A1Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1550US2024043530A1PVRIG Binding Protein And Its Medical UsesJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 1650US2021196719A1Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseasesJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 1749US2023089620A1Anti-IL-2 Antibody, and Antigen-Binding Fragment Thereof and Medical Use ThereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 1849US2025215064A1Bispecific t cell engager and uses thereofMANYSMART THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1949US2024016822A1Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonistSHANGHAI SHENGDI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2049US2024382607A1Drug conjugate of eribulin derivativeSHANGHAI SENHUI MEDICINE CO LTD·Filed 2022·Application pending·0 cites
- 2148US2022025060A1Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2247US12162944B2Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 10, 2024·0 cites·18 claims
- 2347US2023041996A1Calcium-sensing receptor agonist compound and application thereofBEIJING TUO JIE BIOPHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2446US2024189438A1Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicineSHANGHAI SENHUI MEDICINE CO LTD·Filed 2022·Application pending·0 cites
- 2546US2023174670A1Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 2646US2024016946A1Drug-loaded macromolecule and preparation method thereforSHANGHAI SENHUI MEDICINE CO LTD·Filed 2021·Application pending·0 cites
- 2746US2022111008A1Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseasesJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2845US2023405138A1Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 2945US2022017618A1Use of tim-3 antibody in preparation of medicines for treating tumorsJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cheng Liao files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →